AzurRx BioPharma Inc. (NASDAQ: AZRX) Starts Presentation at The LD 500
AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. AzurRx is headquartered in New York with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information, visit the company's website at www.azurrx.com About…







